Combining enzalutamide with abiraterone, prednisone, and androgen deprivation therapy in the STAMPEDE trial - Abstract

There are compelling reasons to study the addition of both enzalutamide and abiraterone, in combination, to standard-of-care for hormone-naïve prostate cancer.

Through a protocol amendment, this will be assessed in the STAMPEDE trial, with overall survival as primary outcome measure.

Written by:
Attard G, Sydes MR, Mason MD, Clarke NW, Aebersold D, de Bono JS, Dearnaley DP, Parker CC, Ritchie AW, Russell JM, Thalmann G, Cassoly E, Millman R, Matheson D, Schiavone F, Spears MR, Parmar MK, James ND.   Are you the author?
The Institute of Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust, London and Sutton, UK; Medical Research Council Clinical Trials Unit at University College London, London, UK; Cardiff University School of Medicine, Velindre Hospital, Cardiff, UK; Department of Urology, The Christie NHS Foundation Trust, Manchester, UK; University of Bern, Bern, Switzerland; 6Medical Research Council Clinical Trials Unit at University College London, London, UK; Institute of Cancer Sciences, University of Glasgow, Glasgow, UK; Department of Urology, University Hospital, Bern, Switzerland; Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland; Patient representative, Stockton-on-Tees, UK; Patient representative, Northampton, UK; University of Warwick, Warwick, UK.  

Reference: Epub ahead of print.
doi: 10.1016/j.eururo.2014.05.038


PubMed Abstract
PMID: 24985962

UroToday.com Prostate Cancer Section

 

 

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe